| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 11.03. | As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026 | ||
| 11.03. | AstraZeneca recruits Joshua Jackson, Philadelphia Flyers' Gritty to cancer screening push | ||
| 11.03. | Veeva shells out $100M for Ostro and its AI chat tool for pharma brand engagement | ||
| 11.03. | Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China | ||
| 11.03. | UCB's Bimzelx continues winning streak with victory over AbbVie's Skyrizi | ||
| 11.03. | J&J's Joaquin Duato joins $30M CEO pay club with 30% compensation boost for 2025 | ||
| 11.03. | Skyhawk taps Teva alum to steer commercial path, while Santhera names new CCO to grow DMD sales | ||
| 10.03. | Sandoz to set up standalone biosimilars unit as it eyes upcoming 'golden decade' of patent losses | ||
| 10.03. | AbbVie's Robert Michael earns hefty pay bump to $32.5M in 2nd year as CEO | ||
| 10.03. | Patients want price transparency, e-commerce experience from pharma DTP platforms: survey | ||
| 10.03. | Novo Nordisk's US headquarters under fire in latest FDA warning letter | ||
| 10.03. | Leerink questions whether BioNTech can thrive without their 'founders' insight' as stock drops | ||
| 10.03. | Filana leaves Cassava Sciences roots behind amid branch into epilepsy | ||
| 10.03. | CSL telegraphs 300 new hires as it breaks ground on $1.5B plasma-based medicine plant near Chicago | ||
| 10.03. | FDA approves leucovorin for ultrarare cerebral folate deficiency subset without clinical trial | ||
| 09.03. | FDA unveils 4th revision of draft guidance for looser biosimilar testing requirements | ||
| 09.03. | Lilly rewards CEO David Ricks with $36.7M pay package for 2025, fueled by GLP-1 success | ||
| 09.03. | Spruce hooks a commercial chief to prep for rare disease launch | ||
| 09.03. | Novo and Hims make nice, striking deal to sell Ozempic, Wegovy on Hims' telehealth platform | ||
| 09.03. | Sotyktu take 2: BMS' first-in-class pill gains FDA nod to treat psoriatic arthritis | ||
| 09.03. | 'SNL' pokes fun at mysteries of Amgen's Otezla for plaque psoriasis | ||
| 09.03. | Novo's troubled Indiana plant claims another victim as FDA rejects Incyte's lung cancer application | ||
| 09.03. | Ipsen backs away from cancer med Tazverik after safety signals emerge in lymphoma trial | ||
| 06.03. | Lonza hands off capsule business to investment firm Lone Star in $3B deal | ||
| 06.03. | Democrats press 11 pharmas for 'any evidence' their Trump pricing deals deliver savings for Medicaid |